Merus Acquires Surgestone®, Provames®, Tredemine® and Speciafoldine® Rights from Sanofi

Merus Labs International Inc. (TSX:MSL, NASDAQ:MSLI) announced the completion of its previously announced acquisition of rights to Surgestone®, Provames®, Tredemine® and Speciafoldine® in France and select other markets from Sanofi.
According to the news:

Merus also confirms that the Subscription Receipts issued onMarch 1, 2016 have converted into Special Warrants on a one-for-one basis in connection with the completion of the acquisition.
Neither the Subscription Receipts, the Special Warrants nor the underlying common shares have been registered under the United States Securities Act of 1933, as amended, and may not be offered or sold within the United States or to, or for the account or benefit of, U.S. persons absent U.S. registration or an applicable exemption from the U.S. registration requirements. This news release does not constitute an offer to sell or the solicitation of an offer to buy any securities.

Click here to view the full press release.